Expert Teaches on Multiple Myeloma on CME Webcast

OSU Wexner Medical Center logo

Expert Teaches on Multiple Myeloma on CME Webcast.  Today’s program is on Multiple Myeloma, but before we can dive deeper into understanding this condition, it’s crucial to distinguish between multiple myeloma and monoclonal gammopathy of undetermined significance or MGUS. Our expert guest today is Dr Srinivas Devarakonda. He is an Associate Professor of Hematology at Ohio State University’s James Cancer Hospital and specializes in plasma cell dyscrasias including multiple myeloma and MGUS.

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to:

  • To explain the clinical scenarios in which to suspect multiple myeloma
  • Explain the diagnostic methods for multiple myeloma
  • To discuss the latest diagnostic criteria and staging system for multiple myeloma
  • Talk briefly about the management of myeloma

You’ll also learn about the following:

  • Symptoms
  • Protein Albumin Gap
  • MGUS
  • Prognosis

You can find this and many other MedNet21 programs on the  OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual.  You can also e-mail him at derrick.freeman@osumc.edu.

Physicians Learn About Multiple Myeloma and MGUS on Webcast

OSUWexnerbloglogo2014 Physicians Learn About Multiple Myeloma and MGUS. Today on MedNet, we’re going to update you on the newest developments in the management of multiple myeloma. We’re pleased to welcome Assistant Professor of Internal Medicine, Dr. Srinivas Devarakonda.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: explain the clinical scenarios in which to suspect multiple myeloma; Explain the diagnostic methods for multiple myeloma; discuss the latest diagnostic criteria and staging system for multiple myeloma; and describe the management of myeloma.

You’ll also learn about the following:

  • Multiple myeloma demographics
  • Multiple myeloma prognosis
  • Evaluation of MGUS
  • When to replace patients with IgG
  • Screening for multiple myeloma
  • Waldenstrom’s macroglobulinemia
  • Kappa versus lambda light chains
  • Future directions in treatment

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.